Glibenclamide—10-h Treatment Window in a Clinically Relevant Model of Stroke
Open Access
- 7 March 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Stroke Research
- Vol. 3 (2), 286-295
- https://doi.org/10.1007/s12975-012-0149-x
Abstract
Glibenclamide improves outcomes in rat models of stroke, with treatment as late as 6 h after onset of ischemia shown to be beneficial. Because the molecular target of glibenclamide, the sulfonylurea receptor 1 (Sur1)-regulated NCCa-ATP channel, is upregulated de novo by a complex transcriptional mechanism, and the principal pathophysiological target, brain swelling, requires hours to develop, we hypothesized that the treatment window would exceed 6 h. We studied a clinically relevant rat model of stroke in which middle cerebral artery occlusion (75% < reduction in LDF signal ≤90%) was produced using an intra-arterial occluder. Recanalization was obtained 4.5 h later by removing the occluder. At that time, we administered recombinant tissue plasminogen activator (rtPA; 0.9 mg/kg IV over 30 min). Immunolabeling showed modest expression of Sur1 5 h after onset of ischemia, with expression increasing 7- to 11-fold (P < 0.01) by 24 h. Rats were administered either vehicle or glibenclamide (10 μg/kg IP loading dose plus 200 ng/h by constant subcutaneous infusion) beginning 4.5 or 10 h after onset of ischemia. In rats treated at 4.5 or 10 h, glibenclamide significantly reduced hemispheric swelling at 24 h from (mean ± SEM) 14.7 ± 1.5% to 8.1 ± 1.6% or 8.8 ± 1.1% (both P < 0.01), respectively, and significantly reduced 48-h mortality from 53% to 17% or 12% (both P < 0.01), and improved Garcia scores at 48 h from 3.8 ± 0.62 to 7.6 ± 0.70 or 8.4 ± 0.74 (both P < 0.01). We conclude that, in a clinically relevant model of stroke, the treatment window for glibenclamide extends to 10 h after onset of ischemia.Keywords
This publication has 33 references indexed in Scilit:
- Sequential Activation of Hypoxia-Inducible Factor 1 and Specificity Protein 1 is Required for Hypoxia-Induced Transcriptional Stimulation ofAbcc8Journal of Cerebral Blood Flow & Metabolism, 2011
- Human Recombinant Tissue-Plasminogen Activator (Alteplase): Why Not Use the ‘Human’ Dose for Stroke Studies in Rats?Journal of Cerebral Blood Flow & Metabolism, 2010
- Glibenclamide Is Superior to Decompressive Craniectomy in a Rat Model of Malignant StrokeStroke, 2010
- Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen ActivatorStroke, 2009
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic StrokeStroke, 2009
- Glibenclamide Reduces Inflammation, Vasogenic Edema, and Caspase-3 Activation after Subarachnoid HemorrhageJournal of Cerebral Blood Flow & Metabolism, 2008
- Endothelial sulfonylurea receptor 1–regulated NCCa-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injuryJCI Insight, 2007
- Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic strokeNature Medicine, 2006
- Inhibition of the Cerebral Ischemic Injury by Ethyl Pyruvate With a Wide Therapeutic WindowStroke, 2005